ANIMATION

Apoptosis and BCL-2

Share this article with:

ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptopic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.

Share It:
Contact XVIVO

Client


Abbvie; Genentech

XVIVO’s professional team met the many challenges posed by a pre-launch product and rendered visually compelling, high quality animations.

Vice President, Management Supervisor, Ogilvy Healthworld Medical Education